Members of the Hematologic Malignancies Program at Rutgers Cancer Institute of New Jersey examined the utilization of a low dose of oral vancomycin, a drug used at higher doses to treat established Clostridium difficile infection (CDI), as a way to prevent CDI in blood and bone marrow transplant (BMT) patients.
The National Comprehensive Cancer Network announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma, one of the most curable forms of pediatric cancer. They synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment.
NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy.
The NCCN Virtual Nursing Forum and Annual Congress: Hematologic Malignancies (#NCCNhem2020) will provide the latest evidence and expert consensus on emerging practices and debates in blood cancer treatment, online October 8-10.
A Rutgers Cancer Institute of New Jersey investigator and other collaborators examined prenatal screening practices for blood disorders between different types of care providers and found different variations in prenatal guidance.
Rutgers Cancer Institute of New Jersey investigators compared outcomes for allogeneic stem cell transplant patients when post-transplant cyclophosphamide (PCy) was added as part of standard treatment than if standard treatment was given alone. Results showed an increase in the number of patients who were free of disease and off immunosuppression at one-year in the PCy cohort.